Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 16/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636099 | 0.90 | UGCG (0.66) | UGCGSMN1; SMN2MITFALDH1A1LMNA | |
| SCHEMBL3103915 | 0.90 | UGCG (0.66) | UGCGSMN1; SMN2MITFALDH1A1LMNA | |
| SCHEMBL3103924 | 0.90 | UGCG (0.66) | UGCGSMN1; SMN2MITFALDH1A1LMNA | |
| SCHEMBL1088908 | 0.86 | UGCG (0.67) | UGCG | |
| SCHEMBL19354950 | 0.86 | UGCG (0.67) | UGCG | |
| SCHEMBL13493071 | 0.84 | UGCG (0.66) | UGCGSMN1; SMN2LMNAHIF1A | |
| SCHEMBL7999211 | 0.84 | UGCG (0.66) | UGCGSMN1; SMN2LMNAHIF1A | |
| SCHEMBL12406950 | 0.84 | UGCG (0.66) | UGCGSMN1; SMN2LMNAHIF1A | |
| SCHEMBL13569487 | 0.84 | UGCG (0.67) | UGCGSMN1; SMN2LMNAHIF1A | |
| SCHEMBL12091640 | 0.84 | UGCG (0.67) | UGCGSMN1; SMN2LMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288556-B2 | 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2481407-A1 | Compounds for use in treating cognitive disorders | Allergan, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120190712-A1 | Methods for Treating Cognitive Disorders | EXONHIT THERAPEUTICS SA (FR) | 2012-07-26 | — | — | US | disclosed |
| US-20120157497-A1 | COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY | ALLERGAN, INC. | 2012-06-21 | — | — | US | disclosed |
| US-8173683-B2 | Methods for treating cognitive disorders | ALLERGAN, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8168631-B2 | 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity | ALLERGAN, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8153666-B2 | Compounds having analgesic and/or immunostimulant activity | ALLERGAN, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100093793-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100048642-A1 | METHODS FOR TREATING COGNITIVE DISORDERS | ALLERGAN, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20090318499-A1 | COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY | ALLERGAN, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090281085-A1 | 3-(4-FLUOROPHENYL)-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC ACTIVITY | ALLERGAN, INC. | 2009-11-12 | — | — | US | disclosed |
| WO-2009100095-A1 | 3-(4-FLUOROPHENYL)-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC ACTIVITY | ALLERGAN, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090036436-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | ALLERGAN, INC. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036436-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | OPRL1, HCAR2, OPRM1 | UGCG 4112/4885SMN1; SMN2 1819/4885MITF 797/4885 |
| US-20090281085-A1 | 3-(4-FLUOROPHENYL)-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC ACTIVITY | OPRL1, OPRK1, OPRM1 | UGCG 3951/4885SMN1; SMN2 2596/4885MITF 3018/4885 |
| US-20090318499-A1 | COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY | OPRK1, OPRM1, OPRL1 | UGCG 3478/4885SMN1; SMN2 740/4885MITF 255/4885 |
| US-20120190712-A1 | Methods for Treating Cognitive Disorders | CHAT, SLC18A3, SLC18A2 | UGCG 556/4885SMN1; SMN2 1059/4885MITF 4720/4885 |
| US-20100048642-A1 | METHODS FOR TREATING COGNITIVE DISORDERS | CHAT, SLC18A3, SLC18A2 | UGCG 556/4885SMN1; SMN2 1059/4885MITF 4720/4885 |
| US-20100093793-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, AADAT, AANAT | UGCG 2208/4885SMN1; SMN2 799/4885MITF 2680/4885 |
| US-20120157497-A1 | COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY | OPRK1, OPRM1, OPRL1 | UGCG 3478/4885SMN1; SMN2 740/4885MITF 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.